Phase 4
Completed N=25
Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients
Source: ClinicalTrials.gov NCT01501929 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcomePrimary: Endothelial Cell Protein Expression p47phox From Endothelial Cell Collection — 0.47; 0.44 Ratio human to HUVEC p47Phox expression
◆ Published Evidence
Emerging
11citations · ~1 / year
Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans.
Summary
The purpose of this study is to determine if Nebivolol improves microvascular perfusion in skeletal muscle during exercise in hypertensive patients and whether this improvement is accompanied by reduction in vascular oxidative stress or increased endothelial nitric oxide synthase (eNOS) expression in humans.
Linked Publications
-
Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Endothelial Cell Protein Expression p47phox From Endothelial Cell Collection |
0.47; 0.44 | — |
| PRIMARY Microvascular Blood Flow |
43.938; 74.584 | — |
Eligibility Criteria
Inclusion Criteria
- Men and women with stage I primary untreated hypertension (BP between 140-159/90-99 mmHg)
- Age 18-65
Exclusion Criteria
- Congestive heart failure
- Coronary artery disease
- Left ventricular hypertrophy by echocardiography or ECG
- History of stroke
- Average blood pressure >159/99 mmHg
- Bradycardia with a resting heart rate 1.4 mg/dL
- Asthma or chronic obstructive pulmonary disease
- Women who are pregnant or planning to become pregnant
- Hypersensitivity to beta blockers, hydrochlorothiazide, or Definity
- Any history of substance abuse (other than tobacco)
- Concomitant drug treatment which raises endogenous nitric oxide levels, including nitrates or phosphodiesterase V inhibitors (Viagra, Levitra)
- History of symptomatic bradycardia or heart block
- Patients with Right-to-left, bidirectional, or transient right-to-left cardiac shunts
- Hypersensitivity to perflutren, blood, blood products or albumin.
Data sourced from ClinicalTrials.gov (NCT01501929) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.